Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107797 | 0.84 | SMN1; SMN2 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7451102 | 0.79 | ALDH1A1 (0.36) | CYP19A1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3525749 | 0.74 | MEN1 (0.39) | ALDH1A1CYP3A4 | |
| SCHEMBL7448786 | 0.70 | CLK4 (0.35) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL7453756 | 0.67 | CLK4 (0.40) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL3527744 | 0.64 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7453259 | 0.64 | CLK4 (0.40) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL7111062 | 0.64 | CLK4 (0.38) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL7109833 | 0.64 | CLK4 (0.35) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL17194888 | 0.63 | CLK4 (0.43) | CLK4DYRK1ACYP19A1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | CLK4 4518/4885DYRK1A 4574/4885CYP19A1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.